To include your compound in the COVID-19 Resource Center, submit it here.

Why liver disease newco Alentis is aiming for one of largest Swiss A rounds

BioMedPartners, BB Pureos Bioventures lead $12M first close for Basel start-up

Liver disease newco Alentis Therapeutics is starting off small with the first close of its series A round, but the additional capital it expects to raise over the next six months could give it the largest series A for a Swiss biotech since 2015.

Founded in

Read the full 453 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE